We will assist in the practical application of drug discovery seeds and the development of pharmaceutical candidate antibodies.
We use human PBMCs (peripheral blood lymphocytes) as materials to clone the target antibody gene using the EBV method and produce fully human monoclonal antibodies. We create a library of healthy human samples consisting of over 100 specimens to assess the likelihood of obtaining the target antibody from healthy individuals. If there are specimens from which we can determine a high probability of acquiring the target antibody based on the results obtained, we can start antibody screening using our owned sample specimens. We emphasize acquiring antibodies that maintain their original activity, producing full-length heavy and light chains without converting them to scFv. 【Features】 - Application of the EBV method - Cloning of the target antibody gene and production of fully human monoclonal antibodies - Emphasis on acquiring antibodies that maintain their original activity - No scFv conversion *For more details, please refer to the catalog or feel free to contact us.
Inquire About This Product
basic information
【Service Overview】 This is a service for producing fully human monoclonal antibodies using human peripheral blood lymphocytes as the material. *For more details, please refer to the catalog or feel free to contact us.*
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the catalog or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
iBeck Co., Ltd. is a company engaged in the manufacturing and sales of fully human antibodies for pharmaceuticals. By utilizing a unique method that does not rely on patents from Europe and the United States, we are able to produce fully human antibodies with fewer side effects. We have developed a technology to produce fully human antibodies from blood B lymphocytes, which are responsible for antibody production in the human body. Additionally, we provide these antibodies to companies involved in antibody pharmaceuticals and engage in joint development as alliance partners.
